Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death?

Advanced gene and cellular therapies risk a second “valley of death” due to their high costs and low patient population. As these are life‐saving therapies, measures are urgently needed to prevent their withdrawal from the market.[Image: see text]

Detalles Bibliográficos
Autores principales: De Luca, Michele, Cossu, Giulio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Science & Society
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900339/
https://www.ncbi.nlm.nih.gov/pubmed/36592141
http://dx.doi.org/10.15252/embr.202256661
_version_ 1784882827929583616
author De Luca, Michele
Cossu, Giulio
author_facet De Luca, Michele
Cossu, Giulio
author_sort De Luca, Michele
collection PubMed
description Advanced gene and cellular therapies risk a second “valley of death” due to their high costs and low patient population. As these are life‐saving therapies, measures are urgently needed to prevent their withdrawal from the market.[Image: see text]
format Online
Article
Text
id pubmed-9900339
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-99003392023-02-09 Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death? De Luca, Michele Cossu, Giulio EMBO Rep Science & Society Advanced gene and cellular therapies risk a second “valley of death” due to their high costs and low patient population. As these are life‐saving therapies, measures are urgently needed to prevent their withdrawal from the market.[Image: see text] John Wiley and Sons Inc. 2023-01-02 /pmc/articles/PMC9900339/ /pubmed/36592141 http://dx.doi.org/10.15252/embr.202256661 Text en © 2022 The Authors. Published under the terms of the CC BY NC ND 4.0 license. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Science & Society
De Luca, Michele
Cossu, Giulio
Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death?
title Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death?
title_full Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death?
title_fullStr Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death?
title_full_unstemmed Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death?
title_short Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death?
title_sort cost and availability of novel cell and gene therapies: can we avoid a catastrophic second valley of death?
topic Science & Society
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900339/
https://www.ncbi.nlm.nih.gov/pubmed/36592141
http://dx.doi.org/10.15252/embr.202256661
work_keys_str_mv AT delucamichele costandavailabilityofnovelcellandgenetherapiescanweavoidacatastrophicsecondvalleyofdeath
AT cossugiulio costandavailabilityofnovelcellandgenetherapiescanweavoidacatastrophicsecondvalleyofdeath

Ejemplares similares